What does LeonaBio, Inc. do?
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule…
What is LeonaBio, Inc.'s P/E and P/B ratio?
LeonaBio, Inc. has a P/E ratio of -0.2 and a P/B ratio of 1.39.
What is LeonaBio, Inc.'s debt-to-equity ratio?
LeonaBio, Inc. has a debt-to-equity ratio of 0.02.
How much does LeonaBio, Inc. owe compared with what it owns?
LeonaBio, Inc. owes $0.41 for every $1 it owns (balance sheet Jun 2026), which is low.
What is LeonaBio, Inc.'s Positivity rank?
LeonaBio, Inc. is ranked #2,275 of 6,774 companies globally and #670 of 4,000 in United States on PositoAI, with a Positivity Score of 21,700.
Does LeonaBio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for LeonaBio, Inc..
Where can I read the latest news about LeonaBio, Inc.?
Recent headlines about LeonaBio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does LeonaBio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of LeonaBio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.